Becton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of Headwinds
The fiscal fourth-quarter revenue at Becton, Dickinson (NYSE: BDX) isn't going to win any growth competitions, but the medical and life sciences conglomerate continues to cut costs, allowing its earnings to grow at a solid clip.
Metric
Q4 2017
Source: Fool.com
Becton, Dickinson & Co. Stock
€218.40
0.650%
Becton, Dickinson & Co. is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
As a result the target price of 268 € shows a positive potential of 22.71% compared to the current price of 218.4 € for Becton, Dickinson & Co..